EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update

Martina Di Franco iD, Lucia Zanoni, Emilia Fortunati, Stefano Fanti, Valentina Ambrosini

Current Oncology Reports · 2024

DOI: 10.1007/s11912-024-01526-5 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology Reports, 2024. Verfasst von Martina Di Franco und 4 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine, Alma Mater Studiorum, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy. martina.difranco2@studio.unibo.it. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Radiopharmaceuticals, Organometallic Compounds. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alma Mater Studiorum - Università di Bologna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose of Review This paper aims to address the latest findings in neuroendocrine tumor (NET) theranostics, focusing on new evidence and future directions of combined diagnosis with positron emission tomography (PET) and treatment with peptide receptor radionuclide therapy (PRRT). Recent Findings Following NETTER-1 trial, PRRT with [177Lu]Lu-DOTATATE was approved by FDA and EMA and is routinely employed in advanced G1 and G2 SST (somatostatin receptor)-expressing NET. Different approaches have been proposed so far to improve the PRRT therapeutic index, encompassing re-treatment protocols, combinations with other therapies and novel indications. Molecular imaging holds a potential added value in characterizing disease biology and heterogeneity using different radiopharmaceuticals (e.g., SST and FDG) and may provide predictive and prognostic parameters. Response assessment criteria are still an unmet need and new theranostic pairs showed preliminary encouraging results. Summary PRRT for NET has become a paradigm of modern theranostics. PRRT holds a favorable toxicity profile, and it is associated with a prolonged time to progression, reduction of symptoms, and improved patients’ quality of life. In light of further optimization, different new strategies have been investigated, along with the development of new radiopharmaceuticals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsRadiopharmaceuticalsOrganometallic CompoundsHumansOctreotidePositron-Emission TomographyReceptors, PeptideTheranostic NanomedicineRadioisotopes

Stichwörter der Autor:innen

NETNeuroendocrine tumorsPETPRRTTheranostics

Substanzen

Radiopharmaceuticalslutetium Lu 177 dotatateOctreotideReceptors, PeptideRadioisotopesOrganometallic Compounds

Autor:innen und Institutionen

  • Nuclear Medicine, Alma Mater Studiorum, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy. martina.difranco2@studio.unibo.it.
  • Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
  • Nuclear Medicine, Alma Mater Studiorum, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy.

ORCID-Profile: Martina Di Franco

Förderung

  • Alma Mater Studiorum - Università di Bologna

Zitieren

APA

Di Franco, M., Zanoni, L., Fortunati, E., Fanti, S., & Ambrosini, V. (2024). Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update. Current Oncology Reports. https://doi.org/10.1007/s11912-024-01526-5

Vancouver

Di Franco M, Zanoni L, Fortunati E, Fanti S, Ambrosini V. Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update. Current Oncology Reports. 2024. doi:10.1007/s11912-024-01526-5

BibTeX
@article{DiFranco2024,
  author = {Di Franco, Martina and Zanoni, Lucia and Fortunati, Emilia and Fanti, Stefano and Ambrosini, Valentina},
  title = {Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update},
  journal = {Current Oncology Reports},
  year = {2024},
  doi = {10.1007/s11912-024-01526-5}
}
Kostenlos starten →